Equities

60 Degrees Pharmaceuticals Inc

SXTP:NAQ

60 Degrees Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.292
  • Today's Change0.002 / 0.76%
  • Shares traded381.69k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

  • Revenue in USD (TTM)378.20k
  • Net income in USD-1.07m
  • Incorporated2022
  • Employees2.00
  • Location
    60 Degrees Pharmaceuticals Inc1025 Connecticut Avenue Nw, Suite 1000WASHINGTON 20036United StatesUSA
  • Phone+1 (202) 327-5422
  • Fax+1 (302) 636-5454
  • Websitehttps://60degreespharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Avenue Therapeutics Inc0.00-7.18m3.24m3.00--0.7159-----39.36-39.360.004.810.00----0.00-123.08-186.91-1,045.52-287.70------------0.00-------192.15------
Optimus Healthcare Services Inc1.27m-7.79m3.32m17.00------2.62-0.1948-0.19480.0317-0.12910.2595--2.1674,453.53-159.79---2,228.37--77.90---615.77--0.1525-15.4121.18--------------
Livewire Ergogenics Inc67.98k-1.09m3.35m1.00------49.25-0.0061-0.00610.0003-0.00220.19791.742.8667,980.00-317.45-------113.70---1,604.38--0.1248-2.13----68.58---3.64------
Manuka Inc671.00k-1.14m3.36m4.00------5.01-0.0128-0.01280.0066-0.01242.410.941237.28167,750.00-410.43-463.75----88.08---170.04-732.150.0194-----------854.23------
Gold River Productions Inc.-100.00bn-100.00bn3.37m1.00k--5.19----------0.0005----------------------------0.00-------100.11------
Eiger Biopharmaceuticals Inc15.77m-74.96m3.41m25.00------0.2159-50.80-50.8010.69-9.770.19850.00649.19630,920.00-94.31-60.25-186.10-76.5199.91---475.26-823.590.6809-22.031.54--16.98--22.54--10.51--
Bio Path Holdings Inc0.00-13.96m3.41m10.00---------27.39-27.390.00-3.480.00----0.00-216.97-70.80-390.65-76.87---------------------15.94------
Altamira Therapeutics Ltd116.94k-8.06m3.43m10.00--0.3157--29.31-31.28-26.400.2384.850.015134.0532.3011,694.20-103.88-73.80-6,364.67-123.19-87.90---6,892.99--1.38-4.360.0152------61.02------
TRACON Pharmaceuticals Inc12.15m1.75m3.43m17.001.97--1.950.28240.65090.65096.27-0.66181.37----714,411.8019.78-79.42---177.85----14.39-813.81---0.4613------32.0587.68------
60 Degrees Pharmaceuticals Inc378.20k-1.07m3.55m2.00------9.37-0.1563-0.15630.05640.61210.04740.88271.90126,066.70-9.87-------23.45---208.43--6.77--0.0217---50.40--35.51------
Clearmind Medicine Inc0.00-8.09m3.58m----0.7104-----30.92-30.920.001.590.00-------109.55-218.20-180.61-488.96-----------2.900.0184-------25.03------
Atreca Inc0.00-97.76m3.65m90.00--0.3391-----2.49-2.490.000.27150.00----0.00-98.54-44.99-116.19-48.05------------0.00------11.13---8.46--
Tharimmune Inc0.00-8.89m3.73m2.00--0.5291-----111.65-111.650.008.970.00----0.00-130.60---173.40--------------0.00-------9.98------
Exicure Inc21.77m2.97m3.84m6.000.25970.85430.99120.17651.711.713.070.521.04----1,674,923.0014.17-41.7542.53-55.57----13.64-302.07----0.00--6,068.1224.2995.97---59.57--
Sentient Brands Holdings Inc0.00-818.63k3.86m2.00---------0.0145-0.01450.00-0.0360.000.0188--0.00-317.87-220.36------41.81---31,451.190.0354-2.27-----73.68--34.98------
Data as of May 31 2024. Currency figures normalised to 60 Degrees Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

4.20%Per cent of shares held by top holders
HolderShares% Held
Central Bank & Trust Co. (KY Invt Mgmt)as of 31 Mar 2024268.00k2.32%
Citadel Securities LLCas of 31 Mar 2024100.63k0.87%
Virtu Americas LLCas of 31 Mar 202459.52k0.51%
Two Sigma Securities LLCas of 31 Mar 202424.19k0.21%
G1 Execution Services LLCas of 31 Mar 202413.55k0.12%
Renaissance Technologies LLCas of 31 Mar 202412.56k0.11%
Tower Research Capital LLCas of 31 Mar 20246.92k0.06%
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 202454.000.00%
Walleye Capital LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.